Xencor Inc. ((XNCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Xencor Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma.’ The study aims to assess the safety and tolerability of XmAb®819, a treatment for patients with relapsed or refractory clear cell renal cell carcinoma, and to determine the minimum safe and biologically active dose.
Intervention/Treatment: The study tests XmAb819, a monoclonal bispecific antibody, administered either intravenously or subcutaneously. The goal is to establish a safe and effective dosing regimen for patients with this type of cancer.
Study Design: This interventional study uses a sequential intervention model with no masking, focusing on treatment as its primary purpose. The study involves dose escalation and expansion phases to determine the optimal dosing schedule.
Study Timeline: The study began on June 13, 2022, and is currently recruiting participants. The last update was submitted on July 28, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
Market Implications: The ongoing study of XmAb819 could influence Xencor Inc.’s stock performance, as positive outcomes may enhance investor confidence and market position. Given the competitive landscape in cancer treatment, advancements in this study could position Xencor favorably against its competitors.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.